InfoMoney PT

Após Ozempic, quando cai a patente do Mounjaro no Brasil?

Após 20 anos de exclusividade do laboratório Novo Nordisk, outras farmacêuticas podem produzir a semaglutida no país The post Após Ozempic, quando cai a patente do Mounjaro no Brasil? appeared first on InfoMoney.

Mar 22, 2026 &03502222202631; 14:50 UTC www.infomoney.com.br Trending 2/5

Read original on www.infomoney.com.br ↗

↘

Negative for markets

Sentiment score: -40/100

Moderate impact Short-term (days)

WHAT THIS MEANS

The expiration of the patent for semaglutide (Ozempic) in Brazil could enable generic competition, potentially reducing Novo Nordisk's revenue from this key drug in the Brazilian market and increasing pressure on its overall profitability. While this development is specific to Brazil and may not significantly impact global operations, it highlights ongoing risks from patent cliffs in the pharmaceutical sector. Investors should assess whether this news is already reflected in stock prices amid broader market dynamics.

AI CONFIDENCE

60% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

Novo Nordisk

NVOStock

Expected to decline

The patent expiration for semaglutide in Brazil may lead to generic competition, eroding Novo Nordisk's market share and revenues in that region, though the market might have anticipated this event.

⇅

S&P 500

^GSPCIndex

High volatility expected

As a major U.S.-listed stock, Novo Nordisk's potential revenue hit could contribute to short-term volatility in broader U.S. indices, depending on sector sentiment.

⇅

Euro Stoxx 50

^STOXX50EIndex

High volatility expected

European pharmaceutical stocks may face indirect pressure from this patent news, affecting indices like STOXX50E if similar expirations are a concern.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider monitoring Novo Nordisk's stock for short-term downside risks due to potential generic entry in Brazil; if bearish indicators persist, hedging with options or diversifying away from pharma stocks may be prudent.

KEY SIGNALS

Patent expirationGeneric competition in emerging markets

SECTORS INVOLVED

Healthcare

Analysis generated on Mar 22, 2026 at 19:37 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by InfoMoney. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Após Ozempic, quando cai a patente do Mounjaro no Brasil?

RELATED INTELLIGENCE